Human medicines European public assessment report (EPAR): Efmody, hydrocortisone, Date of authorisation: 27/05/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Efmody, hydrocortisone, Date of authorisation: 27/05/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Voriconazole Hikma (previously Voriconazole Hospira), voriconazole, Date of authorisation: 27/05/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Voriconazole Hikma (previously Voriconazole Hospira), voriconazole, Date of authorisation: 27/05/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Sun, levetiracetam, Date of authorisation: 14/12/2011, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Sun, levetiracetam, Date of authorisation: 14/12/2011, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Jalra, vildagliptin, Date of authorisation: 19/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Jalra, vildagliptin, Date of authorisation: 19/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Junod, denosumab, Date of authorisation: 23/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Junod, denosumab, Date of authorisation: 23/06/2025, Revision: 1, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.